Business Context and Reporting Period
Company: The Coca-Cola Company (KO)
Filing Type: Form 10-Q (Quarterly Report)
Period: Three and six months ended June 28, 2024
Business Overview: The Company manufactures, markets, and sells non-alcoholic beverage concentrates and syrups. The reporting period reflects seasonal strength typical of the second quarter, with revenue growth driven by pricing initiatives and volume increases in certain regions, partially offset by foreign currency headwinds and significant one-time charges.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 28, 2024 |
Three Months Ended June 30, 2023 |
Six Months Ended June 28, 2024 |
Six Months Ended June 30, 2023 |
|---|---|---|---|---|
| Net Operating Revenues | $12,363 | $11,972 | $23,663 | $22,952 |
| Gross Profit | $7,551 | $7,060 | $14,616 | $13,723 |
| Operating Income | $2,632 | $2,401 | $4,773 | $5,768 |
| Net Income (Attributable to Shareowners) | $2,411 | $2,547 | $5,588 | $5,654 |
| Diluted EPS | $0.56 | $0.59 | $1.29 | $1.30 |
| Operating Cash Flow (6mo) | $4,113 | $4,629 | ||
| Free Cash Flow (6mo) (Op Cash Flow - CapEx) |
||||
| Total Debt (Long-term + Current) | $41,817 (as of June 28, 2024) | |||
| Cash & Equivalents | $13,708 (as of June 28, 2024) |
Margins (Six Months):
- Gross Margin: 61.8% (vs. 59.8% in 2023)
- Operating Margin: 20.2% (vs. 25.1% in 2023)
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenues increased 3% year-over-year for both the quarter and the six-month period. This was driven by a 9% favorable impact from price, product, and geographic mix, partially offset by a 6% unfavorable impact from foreign currency fluctuations.
- Volume Trends: Worldwide unit case volume increased 2% for the quarter and 2% for the six months. Concentrate sales volume increased 5% for the quarter and 1% for the six months.
- Operating Income Decline (6mo): Operating income decreased 17% to $4.77 billion for the six months ended June 28, 2024. This decline was primarily due to higher "Other Operating Charges" and the impact of refranchising bottling operations, which reduced consolidated revenue and operating income from those specific assets.
- Other Operating Charges: Charges increased significantly to $2.94 billion for the six months ended June 28, 2024 (vs. $1.45 billion in 2023). Key drivers included:
- $2.10 billion related to the remeasurement of contingent consideration for the fairlife acquisition.
- $760 million impairment charge related to the BodyArmor trademark.
- Divestitures: The Company recognized net gains of $1.4 billion in "Other Income (Loss) - net" from the refranchising of bottling operations in the Philippines, India, and the sale of an equity interest in Thailand.
Guidance, Outlook, and Risks
- Foreign Exchange Outlook: Management expects foreign currency exchange rate fluctuations to have an unfavorable impact on full-year 2024 net operating revenues and operating income based on current spot rates and hedging coverage.
- Capital Allocation: Priorities include investing in operations, growing dividends, and share repurchases to offset dilution. The Company expects 2024 capital expenditures to be approximately $2.2 billion.
- Tax Litigation Risk: The Company is in ongoing litigation with the IRS regarding transfer pricing for tax years 2007-2009. While the Company believes it is more likely than not to prevail on appeal, a potential aggregate incremental tax and interest liability of approximately $16 billion (as of Dec 31, 2023) could materialize if the Tax Court methodology is upheld and applied to subsequent years. A payment of approximately $6.0 billion related to the 2007-2009 years is expected to be made by the end of 2024 pending the Tax Court decision.
- BodyArmor Impairment: The $760 million impairment of the BodyArmor trademark was driven by revised operating projections and higher discount rates. Management noted that if near-term results do not meet revised projections, additional impairment charges may be required.
Investor Verification Checklist
- Tax Litigation Exposure: Verify the status of the IRS transfer pricing dispute and the potential $16 billion liability exposure, including the timing of the expected $6.0 billion payment.
- BodyArmor Performance: Monitor future operating results for the BodyArmor brand to assess the risk of further impairment charges following the $760 million write-down.
- Foreign Currency Impact: Track the strength of the U.S. dollar against key currencies (Argentine peso, Nigerian naira, Turkish lira) as this continues to negatively impact reported revenues and operating income.
- Refranchising Impact: Analyze the long-term financial impact of the refranchising of bottling operations in the Philippines, Bangladesh, and India on consolidated revenue and operating income.
- fairlife Contingent Consideration: Review the fairlife acquisition milestone payment obligations and the volatility of the contingent consideration liability remeasurement.